Lack of desensitization and enhanced efficiency of calcium channel promoter in conscious dogs with heart failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 275, Issue 6 44-6, 1998, Pages

  Asai, Kuniya ^a   Uechi, Masami ^a   Sato, Naoki ^a   Shen, Weiqun ^a   Meguro, Tomomi ^a   Mathier, Michael A ^a   Shannon, Richard P ^a   Vatner, Stephen F ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Catecholamine; Inottopic agents; Myocardial contractility; Myocardial efficiency; Myocardial oxygen consumption

Indexed keywords

2 AMINO 5 CYANO 6 METHYL 4 (3 PHENYL 5 QUINOLINYL) 3 PYRIDINECARBOXYLIC ACID ISOPROPYL ESTER; CALCIUM CHANNEL; CALCIUM CHANNEL STIMULATING AGENT; DOBUTAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHANNEL GATING; CONTROLLED STUDY; DOG; FEMALE; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; INOTROPISM; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

EID: 33750886739     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1998.275.6.h2219     Document Type: Article

References (31)

1. Bechem, M., S. Goldmann, R. Gross, S. Hallermann, S. Hebisch, J. Hütter, H.-P. Rounding, M. Schramm, J. Stoltefuss, and A. Straub. A new type of Ca-channel modulation by a novel class of 1,4- dihydropyridines. Life Sci. 60: 107-118, 1997.
2. Bristow, M. R., R. Ginsburg, W. Minobe, R. S. Cubicciotti, W. S. Sageman, K. Lurie, M. E. Billingham, D. C. Harrison, and E. B. Stinson. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N. Engl. J. Med. 307: 205-211, 1982.
3. Burkhoff, D., and K. Sagawa. Ventricular efficiency predicted by an analytical model. Am. J. Physiol. 250 (Regulatory Integrative Comp. Physiol. 19): R1021-R1027, 1986.
4. Feldman, M. D., L. Copelas, J. K. Gwathmey, P. Phillips, S. E. Warren, F. J. Schoen, W. Grossman, and J. P. Morgan. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 75: 331-339, 1987.
5. Fowler, M. B., J. A. Laser, G. L. Hopkins, W. Minobe, and M. R. Bristow. Assessment of the β-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 74: 1290-1302, 1986.
6. Grandis, D. J., P. J. DelNido, and A. P. Koretsky. Functional and energetic effects of the inotropic agents EMD-57033 and BAPTA on the isolated rat heart. Am. J. Physiol. 269 (Cell Physiol. 38): C472-C479, 1995.
7. Grossman, W. Evaluation of systolic and diastolic function of the myocardium. In: Cardiac Catheterization, Angiography, and Intervention (5th ed.), edited by D. S. Baim and W. Grossman. Baltimore, MD: Williams and Wilkins, 1996, p. 333-335.
8. Hasenfuss, G., C. Holubarsch, H. W. Heiss, and H. Just. Influence of UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Am. Heart J. 118: 512-519, 1989.
9. Hata, K., Y. Goto, S. Futaki, Y. Ohgoshi, H. Yaku, O. Kawaguchi, T. Takasago, A. Saeki, T. W. Taylor, T. Nishioka, and H. Suga. Mechanoenergetic effects of pimobendan in canine left ventricles. Comparison with dobutamine. Circulation 86: 1291-1301, 1992.
10. Holubarsch, C., G. Hasenfuss, H. W. Heiss, T. Meinertz, and H. Just. Acute and chronic changes of myocardial energetics in the mammalian and human heart. Basic Res. Cardiol. 82, Suppl. II: 377-388, 1987.
11. Kass, D. A., M. Midei, W. Graves, J. A. Brinker, and W. L. Maughan. Use of a conductance (volume) catheter and transient inferior vena caval occlusion for rapid determination of pressure-volume relationships in man. Cathet. Cardiovasc. Diagn. 15: 192-202, 1988.
12. Katz, A. M. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 73, Suppl. III: III-184-III-190, 1986.
13. Kiuchi, K., R. P. Shannon, K. Komamura, D. J. Cohen, C. Bianchi, C. J. Homcy, S. F. Vatner, and D. E. Vatner. Myocardial β-adrenergic receptor function during the development of pacing-induced heart failure. J. Clin. Invest. 91: 907-914, 1993.
14. Kostis, J. B., C. R. Lacy, J. J. Raia, J. H. Dworkin, R. G. Warner, and L. A. Casazza. DPI 201-106 for severe congestive heart failure. Am. J. Cardiol. 60: 1334-1339, 1987.
15. Kubo, S. H., S. Gollub, R. Bourge, P. Rahko, F. Cobb, M. Jessup, S. Brozena, M. Brodsky, P. Kirlin, J. Shanes, M. Konstam, A. Gradman, J. Morledge, M. Cinquegrani, S. Singh, T. LeJemtel, J. Nicklas, J. Troha, and J. N. Cohn. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. Circulation 85: 942-949, 1992.
16. Mori, M., M. Takeuchi, H. Takaoka, K. Hata, Y. Hayashi, H. Yamakawa, and M. Yokoyama. Oxygen-saving effect of a new cardiotonic agent, MCI-154, in diseased human hearts. J. Am. Coll. Cardiol. 29: 613-622, 1997.
17. Nielsen-Kudsk, J. E., and J. Aldershvile. Will calcium sensitizers play a role in the treatment of heart failure? J. Cardiovasc. Pharmacol. 26, Suppl. 1: S77-S84, 1995.
18. Ohte, N., C. P. Cheng, M. Suzuki, and W. C. Little. The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure. J. Pharmacol. Exp. Ther. 282: 23-31, 1997.
19. Pagani, M., H. Baig, A. Sherman, W. T. Manders, P. Quinn, T. Patrick, D. Franklin, and S. F. Vatner. Measurement of multiple simultaneous small dimensions and study of arterial pressure-dimension relations in conscious animals. Am. J. Physiol. 235 (Heart Circ. Physiol. 4): H610-H617, 1978.
20. Pagel, P. S., M. F. McGough, D. A. Hettrick, D. Lowe, J. P. Tessmer, I. N. Jamali, and D. C. Warltier. Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J. Cardiovasc. Pharmacol. 29: 563-573, 1997.
21. Permanetter, B., H. Sebening, F. Hartmann, G. Baumann, and L. Lutilsky. Effect of intravenous pimobendan (UDCG 115 BS) on hemodynamics and left ventricular volumes in idiopathic dilative cardiomyopathy. J. Cardiovasc. Pharmacol. 14: 803-809, 1989.
22. Rankin, J. S., P. A. McHale, C. E. Arentzen, D. Ling, J. C. Greenfield, Jr., and R. W. Anderson. The three-dimensional dynamic geometry of the left ventricle in the conscious dog. Circ. Res. 39: 304-313, 1976.
23. Remme, W. J., D. A. C. M. Kruijssen, D. C. A. van Hoogenhuyze, X. H. Krauss, G. L. Bartels, C. J. Storm, and P. W. de Leeuw. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. J. Cardiovasc. Pharmacol. 24: 730-739, 1994.
24. ++ sensitivity of contractile proteins. Circulation 73, Suppl. III: III-78-III-84, 1986.
25. Sato, N., M. Uechi, K. Asai, T. Patrick, R. K. Kudej, and S. F. Vatner. Effects of a novel inotropic agent, BAY y 5959, in conscious dogs: comparison with dobutamine and milrinone. Am. J. Physiol. 272 (Heart Circ. Physiol. 41): H753-H759, 1997.
26. 2+ channels. Nature 303: 535-537, 1983.
27. Simaan, J. A., G. Fawaz, and K. Jabbour. Comparison of the cardiodynamic and metabolic effects of dobutamine with those of norepinephrine and dopamine in the dog isolated heart. Naunyn Schmiedebergs Arch. Pharmacol. 338: 174-179, 1988.
28. 2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor. Am. Heart J. 133: 283-289, 1997.
29. Teramura, S., T. Yamakado, M. Maeda, and T. Nakano. Effects of MCI-154, a calcium sensitizer, on left ventricular systolic and diastolic function in pacing-induced heart failure in the dog. Circulation 95: 732-739, 1997.
30. Tisdale, J. E., R. Patel, C. R. Webb, S. Borzak, and B. J. Zarowitz. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog. Cardiovasc. Dis. 38: 167-180, 1995.
31. Uechi, M., K. Asai, N. Sato, and S. F. Vatner. A voltage-dependent calcium channel promoter restores baroreflex sensitivity in conscious dogs with heart failure. Circulation 98: 1342-1347, 1998.